American Biogenetic Sciences Inc. (NASDAQ:MABXA) ofCopiague, N.Y., has entered into a licensing arrangement withUniversity College Dublin (UCD) and UCD faculty member CiaranRegan to develop a new pharmaceutical agent designed todelay the progression of Alzheimer's disease. The company saidthat studies in lab animals have shown that the new, unnamedcompound can restore the brain-damaged animals' ability toperform various memory tests.

(c) 1997 American Health Consultants. All rights reserved.